Search

Author/Creator D'Haens, G R

1. A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function. Issue 4 (14th March 2019)

Authors:
De Vries, L C S; Duarte, J M; De Krijger, M; Welting, O; Van Hamersveld, P H P; Van Leeuwen-Hilbers, F W M; Moerland, P D; Jongejan, A; D'Haens, G R; De Jonge, W J; Wildenberg, M E
Journal:
Inflammatory bowel diseases
Issue:
Volume 25:Issue 4(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function. Issue 4 (19th January 2019)

Authors:
De Vries, L C S; Duarte, J M; De Krijger, M; Welting, O; Van Hamersveld, P H P; Van Leeuwen-Hilbers, F W M; Moerland, P D; Jongejan, A; D'Haens, G R; De Jonge, W J; Wildenberg, M E
Journal:
Inflammatory bowel diseases
Issue:
Volume 25:Issue 4(2019)
Page Start:
647
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. DOP023 Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trials. (16th January 2018)

Authors:
Sandborn, W J; Panés, J; D'Haens, G R; Sands, B E; Su, C; Moscariello, M; Jones, T V; Pedersen, R D; Friedman, G S; Lawendy, N; Chan, G
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S045
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. DOP61 Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with Ulcerative Colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING study. (27th May 2021)

Authors:
Sandborn, W J; Dubinsky, M C; Torres, J; Vermeire, S; Kotze, P G; Su, C; Lawendy, N; Paulissen, J; Mundayat, R; Gardiner, S; Kulisek, N; Modesto, I; D'Haens, G R
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S096
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial. (21st January 2022)

Authors:
Peyrin-Biroulet, L; Vermeire, S; D'Haens, G R; Panés, J; Dignass, A; Magro, F; Le Bars, M; Lahaye, M; Nazar, M; Ni, L; Bravatà, I; Lavie, F; Daperno, M; Lukáš, M; Armuzzi, A; Löwenberg, M; Gaya, D R; Danese, S
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i132
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. OP024 Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn's disease: the OPERA II study. (16th January 2018)

Authors:
D'Haens, G R; Reinisch, W; Lee, S D; Tarabar, D; Louis, E; Kłopocka, M; Klaus, J; Schreiber, S; Park, D I; Hébuterne, X; Cataldi, F; Banerjee, A; Gorelick, K; Sandborn, W J
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S017
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. OP18 Efficacy and safety of filgotinib for the treatment of perianal fistulizing Crohn's Disease: Results from the phase 2 DIVERGENCE 2 study. (21st January 2022)

Authors:
Reinisch, W; Colombel, J F; D'Haens, G R; Rimola, J; DeHaas-Amatsaleh, A; McKevitt, M; Ren, X; Serone, A; Schwartz, D A; Gecse, K B
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i019
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. OP26 Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies. (27th May 2021)

Authors:
Schreiber, S W; Ferrante, M; Panaccione, R; Colombel, J F; Hisamatsu, T; Lim, A; Lindsay, J O; Rubin, D T; Sandborn, W J; Neimark, E; Song, A P; Liao, X; Feng, T; Berg, S; Wallace, K; D'Haens, G R
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S026
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies. (27th May 2021)

Authors:
Bossuyt, P; Ferrante, M; Baert, F; Danese, S; Feagan, B G; Loftus Jr, E V; Panés, J; Peyrin-Biroulet, L; Ran, Z; Armuzzi, A; D'Haens, G R; Song, A; Neimark, E; Liao, X; Zhou, Q; Berg, S; Wallace, K; Panaccione, R
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S033
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗